Anthony Griffiths

Associate Professor, Microbiology

Emerging infectious diseases can have enormous consequences locally and globally.  Our group works to understand the biology of emerging and reemerging viruses in high and maximum containment, and to deploy this knowledge to develop vaccines and therapies.  Some of this work supports our Nonclinical Studies Unit to perform advanced development of vaccines and therapeutics for GLP studies or licensure via the FDA Animal Rule.

We have spent a long time studying filoviruses.  The family Filoviridae includes Ebola virus and Marburg virus, which are associated with sporadic outbreaks and high case fatality rates. A maximum containment laboratory (Biosafety Level 4) is required to study the infectious forms of these viruses. Dr. Griffiths’ laboratory is interested in multiple aspects of filovirus biology with a view to exploiting this knowledge to further the development of vaccines and therapeutics.

Since the start of the SARS-CoV-2 pandemic, we have pivoted to support mitigation efforts.  These have involved development of assays to quantify immune responses, evaluation medical countermeasures in vitro and in animal models, and assessments of inactivation methods.

 

Selected Publications

  1. Zhang, Q, Honko, A, Zhou, J, Gong, H, Downs, S. N, Vasquez, J. H, Fang, R. H, Gao, W, Griffiths, A, & Zhang, L. (2020) Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity.Nano Letters
  2. Atyeo, Caroline and Slein, Matthew D. and Fischinger, Stephanie and Burke, John and Schӓfer, Alexandra and Leist, Sarah R. and Honko, Anna and Johnson, Rebecca and Storm, Nadia and Bernett, Matthew and Linde, Caitlyn and Suscovich, Todd and Griffiths, Anthony and Desjarlais, John R. and Juelg, Boris D. and Goudsmit, Jaap and Baric, Ralph and Alter, Galit, Therapeutic Potential of SARS-CoV-2-Specific Monoclonal Antibody CR3022. Available at SSRN: https://ssrn.com/abstract=3612156 or http://dx.doi.org/10.2139/ssrn.3612156
  3. Structure of the full SARS-CoV-2 RNA genome in infected cells. Tammy C. T. Lan, Matthew F. Allan, Lauren E. Malsick, Stuti Khandwala, Sherry S. Y. Nyeo, Mark Bathe, Anthony Griffiths, Silvi Rouskin. bioRxiv 2020.06.29.178343; doi: https://doi.org/10.1101/2020.06.29.178343
  4. Nadia Storm, Lindsay McKay, Sierra Downs , Rebecca Johnson, Dagnachew Birru, Marc de Samber, Walter Willaert, Giovanni Cennini, Anthony Griffiths . Rapid and complete inactivation of SARS-CoV-2 by ultraviolet-C irradiation, 03 September 2020, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-65742/v1]
  5. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro. Tianshu Xiao, Jianming Lu, Jun Zhang, Rebecca I. Johnson, Lindsay G.A. McKay, Nadia Storm, Christy L. Lavine, Hanqin Peng, Yongfei Cai, Sophia Rits-Volloch, Shen Lu, Brian D. Quinlan, Michael Farzan, Michael S. Seaman, Anthony Griffiths, Bing Chen. bioRxiv 2020.09.18.301952; doi: https://doi.org/10.1101/2020.09.18.301952
  6. Alfson, K, Avena, L, Beadles, M, Worwa, G, Amen, M, Patterson, J, Jr., R. C, & Griffiths, A. (2018)Intramuscular Exposure of Macacafascicularis to Low Doses of Low Passage- or Cell Culture- Adapted Sudan Virus or Ebola Virus.Viruses 10, 642 —- 18
  7. Alfson, K. J, Worwa, G, Jr., R. C, & Griffiths, A. (2016) Determination and Therapeutic Exploitationof Ebola Virus Spontaneous Mutation Frequency.Journal of virology 90, 2345–2355